Mr. William Williams reports

BRIACELL ADDS MAYO CLINIC TO PHASE 3 STUDY IN METASTATIC BREAST CANCER

Briacell Therapeutics Corp. has added a key clinical site, Mayo Clinic, to its continuing pivotal phase 3 clinical study in metastatic breast cancer.

Briacell's phase 3 study has 69 active clinical sites across 15 states, including Mayo Clinic, DHR Health Oncology Institute, Hematology Oncology Associates of Fredericksburg, Los Angeles Cancer Network, Manhattan Hematology/Oncology Associates, New York Cancer & Blood Specialists, Northwestern University, Smilow Cancer Hospital at Yale New Haven, Sylvester Comprehensive Cancer Center, Texas Oncology-Baylor Charles A. Sammons Cancer Center, and University of Arizona.

"We are very excited to be working with renowned clinical experts at a leading cancer centre like Mayo Clinic, who also participated in Briacell's phase 2 study," stated Dr. Giuseppe Del Priore, Briacell's chief medical officer. "We strongly believe that our novel immunotherapy has the potential to transform cancer care for patients and their families."

Briacell's pivotal phase 3 clinical study is evaluating Briacell's lead clinical candidate, Bria-IMT, plus immune checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer.

Interim data will be analyzed once 144 patient events (deaths) occur, comparing the overall survival in patients treated with the Bria-IMT combination regimen versus those treated with physician's choice as the primary end point. Briacell recently (ASCO 2025) announced positive phase 2 survival data in a similar MBC patient population treated with the same Bria-IMT combination regimen. The Bria-IMT combination regimen has received Food and Drug Administration fast-track designation.

About Briacell Therapeutics Corp.

Briacell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care.

We seek Safe Harbor.